Comparison of outcomes for African Americans, Hispanics, and non-Hispanic whites in the CATIE study

Psychiatric Services

Volumn 64, Issue 6, 2013, Pages 570-578

  Arnold, Jodi Gonzalez ^a   Miller, Alexander L ^a   Cañive, José M ^b,c   Rosenheck, Robert A ^d   Swartz, Marvin S ^e   Mintz, Jim ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b New Mexico Veterans Affairs (VA) Healthcare System   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADD ON THERAPY; ADULT; AFRICAN AMERICAN; AGED; AKATHISIA; CAUCASIAN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HEALTH CARE DISPARITY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARKINSONISM; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; SCHIZOPHRENIA; SOCIAL STATUS; TREATMENT WITHDRAWAL;

ADULT; AFRICAN AMERICANS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DROPOUTS; PERPHENAZINE; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES; UNITED STATES; YOUNG ADULT;

EID: 84883146592     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.002412012     Document Type: Review

References (42)

1. Kessler RC, Birnbaum H, Demler O, et al: The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biological Psychiatry 58:668-676, 2005
2. Lawson WB, Herman BK, Loebel A, et al: Ziprasidone in black patients with schizophrenia: analysis of four short-term, double-blind studies. CNS Spectrums 14: 478-486, 2009
3. Kattura RS: Relationships between ethnicities and treatment outcomes in schizophrenia patients. Dissertation, University of Texas at Austin, College of Pharmacy, 2008
4. Ruiz P, Varner RV, Small DR, et al: Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatric Quarterly 70: 163-172, 1999
5. Glazer WM, Morgenstern H, Doucette J: Race and tardive dyskinesia among outpatients at a CMHC. Hospital and Community Psychiatry 45:38-42, 1994
6. Kreyenbuhl J, Zito JM, Buchanan RW, et al: Racial disparity in the pharmacological management of schizophrenia. Schizophrenia Bulletin 29:183-193, 2003
7. Frackiewicz EJ, Herrera JM, Sramek JJ, et al: Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study. Psychiatry 65:371-374, 2002
8. Miller AL, Crismon ML, Rush AJ, et al: The Texas Medication Algorithm Project: clinical results for schizophrenia. Schizophrenia Bulletin 30:627-647, 2004
9. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-1223, 2005
10. Stroup TS, McEvoy JP, Swartz MS, et al: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29: 15-31, 2003
11. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCIDCV). Washington, DC, American Psychiatric Press, 1996
12. Swartz MS, Perkins DO, Stroup TS, et al: Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophrenia Bulletin 29: 33-43, 2003
13. Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry Supplement 7: 59-67, 1989
14. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13:261-276, 1987
15. Addington D, Addington J, Maticka-Tyndale E, et al: Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research 6:201-208, 1992
16. Addington D, Addington J, Schissel B: A depression rating scale for schizophrenics. Schizophrenia Research 3: 247-251, 1990
17. Tracy K, Adler LA, Rotrosen J, et al: Interrater reliability issues in multicenter trials, part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study 394. Psychopharmacology Bulletin 33:53-57, 1997
18. Barnes TR: A rating scale for drug-induced akathisia. British Journal of Psychiatry 154: 672-676, 1989
19. Vega WA, Karno M, Alegría M, et al: Research issues for improving treatment of US Hispanics with persistent mental disorders. Psychiatric Services 58:385-394, 2007
20. Stauffer V, Case M, Kollack-Walker S, et al: Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophrenia Research 130:11-19, 2011
21. Fijal BA, Stauffer VL, Kinon BJ, et al: Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. Journal of Clinical Psychiatry 73:367-371, 2012
22. Bigos KL, Bies RR, Pollock BG, et al: Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Molecular Psychiatry 16:620-625, 2011
23. Bigos KL, Pollock BG, Coley KC, et al: Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology 48:157-165, 2008
24. Delahanty J, Ram R, Postrado L, et al: Differences in rates of depression in schizophrenia by race. Schizophrenia Bulletin 27:29-38, 2001
25. Chakos M, Patel JK, Rosenheck R, et al: Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study. Clinical Schizophrenia and Related Psychoses 5:124-134, 2011
26. Gonzalez JM, Bowden CL, Berman N, et al: One-year treatment outcomes of African-American and Hispanic patients with bipolar I or II disorder in STEP-BD. Psychiatric Services 61:164-172, 2010
27. Hampton MD, White MC, Chafetz L: Eligibility, recruitment, and retention of African Americans with severe mental illness in community research. Community Mental Health Journal 45:137-143, 2009
28. Lesser IM, Castro DB, Gaynes BN, et al: Ethnicity/race and outcome in the treatment of depression: results from STAR*D. Medical Care 45:1043-1051, 2007
29. Whaley AL: Cultural mistrust of white mental health clinicians among African Americans with severe mental illness. American Journal of Orthopsychiatry 71: 252-256, 2001
30. Whaley AL: Cultural mistrust and mental health services for African Americans: a review and meta-analysis. Counseling Psychologist 29:513-531, 2001
31. Corbie-Smith G, Thomas SB, St George DM: Distrust, race, and research. Archives of Internal Medicine 162:2458-2463, 2002
32. Lester K, Resick PA, Young-Xu Y, et al: Impact of race on early treatment termination and outcomes in posttraumatic stress disorder treatment. Journal of Consulting and Clinical Psychology 78: 480-489, 2010
33. Guarnaccia PJ, Parra P: Ethnicity, social status, and families' experiences of caring for a mentally ill family member. Community Mental Health Journal 32:243-260, 1996
34. Kupfer DJ, Frank E, Grochocinski VJ, et al: African-American participants in a bipolar disorder registry: clinical and treatment characteristics. Bipolar Disorders 7:82-88, 2005
35. Mueser KT, Essock SM, Drake RE, et al: Rural and urban differences in patients with a dual diagnosis. Schizophrenia Research 48:93-107, 2001
36. Montross LP, Barrio C, Yamada AM, et al: Tri-ethnic variations of co-morbid substance and alcohol use disorders in schizophrenia. Schizophrenia Research 79: 297-305, 2005
37. Horvitz-Lennon M, McGuire TG, Alegría M, et al: Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia. Health Services Research 44:2106-2122, 2009
38. Alegría M, Chatterji P, Wells K, et al: Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatric Services 59: 1264-1272, 2008
39. Blow FC, Zeber JE, McCarthy JF, et al: Ethnicity and diagnostic patterns in veterans with psychoses. Social Psychiatry and Psychiatric Epidemiology 39:841-851, 2004
40. Dixon L, Green-Paden L, Delahanty J, et al: Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. Psychiatric Services 52:1216-1222, 2001
41. Copeland LA, Zeber JE, Valenstein M, et al: Racial disparity in the use of atypical antipsychotic medications among veterans. American Journal of Psychiatry 160: 1817-1822, 2003
42. Miranda J, Bernal G, Lau A, et al: State of the science on psychosocial interventions for ethnic minorities. Annual Review of Clinical Psychology 1:113-142, 2005